[{"id":"237b354a-5aa6-4026-9efe-63dba3502553","acronym":"","url":"https://clinicaltrials.gov/study/NCT05451849","created_at":"2022-07-11T11:54:54.962Z","updated_at":"2024-07-02T16:35:16.022Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer","source_id_and_acronym":"NCT05451849","lead_sponsor":"TCR2 Therapeutics","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TC-510"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 06/21/2022","start_date":" 06/21/2022","primary_txt":" Primary completion: 10/30/2028","primary_completion_date":" 10/30/2028","study_txt":" Completion: 10/30/2028","study_completion_date":" 10/30/2028","last_update_posted":"2024-03-06"}]